Search Results - "Morgan, G.J."

Multiple Myeloma Biological Pathways by Morgan, G.J

Get full text

Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden by Giles, S.L, deSouza, N.M, Collins, D.J, Morgan, V.A, West, S, Davies, F.E, Morgan, G.J, Messiou, C

“…Aim To estimate and compare the extent of myeloma bone disease by skeletal region using whole-body diffusion-weighted imaging (WB-DWI) and skeletal survey (SS)…”
Get full text

The impact of normal plasma cell recovery on progression-free and overall survival in myeloma patients after ASCT by Rawstron, A.C, Gregory, W.M, de Tute, R.M, Davies, F.E, Bell, S.E, Drayson, M.T, Cook, G, Jackson, G.H, Morgan, G.J, Childf, J.A, Owen, R.G

Get full text

Presentation free light chain levels and age are the strongest predictors of renal function in newly diagnosed multiple myeloma patients by Yadav, P, Cockwell, P, Cook, M, Pinney, J, Giles, H, Aung, Y.S, Gregory, W.M, Owen, R.G, Davies, F.E, Jackson, G.H, Child, A, Morgan, G.J, Drayson, M

Get full text

High versus attenuated dose dexamethasone has little effect on the speed or depth of response to induction therapy for myeloma by Giles, H, Ferretti, L, Cook, M, Aung, Y.S, Yadav, P, Cockwell, P, Pinney, J, Davies, F.E, Gregory, W.M, Owen, R.G, Jackson, G.H, Child, J.A, Morgan, G.J, Drayson, M

Get full text

Renal Function and Age at Presentation and Serum Free Light Chain Response at Post-induction Predict Renal Outcome by Yadav, P, Cockwell, P, Cook, M, Pinney, J, Giles, H, Aung, Y.S, Gregory, W.M, Owen, R.G, Davies, F.E, Jackson, G.H, Child, A, Morgan, G.J, Drayson, M

Get full text

Jumping Translocations of 1q12 in Multiple Myeloma: Unexpected Intra-clonal Heterogeneity of Copy Number Aberrations in the 1q21-31 Region by Sawyer, J, Tian, E, Heuck, C.J, Johann, D.J, Swanson, C.M, Lukacs, J.L, Binz, R.L, Sammartino, G, Zangari, M, Davies, F.E, van Rhee, F, Barlogie, B, Morgan, G.J

Get full text

Molecular risk stratification of 1,036 cases from the NCRI Myeloma XI trial using the all-molecular diagnostic tool MyMaP (Myeloma MLPA and translocation PCR) by Kaiser, M.F, Boyle, E.M, Walker, B.A, Johnson, D, Pawlyn, C, Jones, J, Begum, D, Proszek, P, Dahir, N, Savola, S, Owen, R.G, Drayson, M.T, Cairns, D.A, Cook, G, Gregory, W, Davies, F.E, Jackson, G, Morgan, G.J

Get full text

Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI trial by de Tute, R, Rawstron, A.C, Cairns, D, Pawlyn, C, Davies, F, Collett, C, Jones, J, Kaiser, M, Chalmers, A, Striha, A, Cook, G, Russell, N, Drayson, M.T, Gregory, W.M, Jackson, G.H, Morgan, G.J, Owen, R.G

Get full text

The spectrum and clinical impact of epigenetic modifier mutations in myeloma by Pawlyn, C, Kaiser, M.F, Heuck, C, Melchor, L, Wardell, C.P, Murison, A, Chavan, S, Johnson, D.C, Begum, D, Proszek, P, Cairns, D.A, Boyle, E.M, Jones, J.R, Cook, G, Drayson, M.T, Owen, R.G, Gregory, W.M, Jackson, G.H, Barlogie, B, Davies, F.E, Walker, B.A, Morgan, G.J

Get full text

Multiple Myeloma Subtyping That Associates Normal B-Cell Subset Phenotypes, do Correlate to Disease Stage and Prognosis - Indication of Reversible Phenotypic Plasticity as a Hallmark by Johnsen, H.E, Bødker, J.S, Schmitz, A, Falgreen, S, Perez-Andres, M, Samur, M.K, Davies, F, Pawlyn, C, Kaiser, M, Johnson, D, Bertsch, U, Broijl, A, van Duin, M, Shah, R, Kjeldsen, M.K, Bergkvist, K.S, Bilgrau, A.E, Johansen, P, El-Galaly, T.C, Samworth, R, Sonneveld, P, Goldschmidt, H, Morgan, G.J, Orfao, A, Munshi, N, Dybkær, K, Bøgsted, M

Get full text

Results of the Medical Research Council (MRC) Myeloma IX study: Effects of zoledronic acid (ZOL) on overall survival (OS) in patients with multiple myeloma (MM) by Morgan, G.J, Davies, F.E, Gregory, W.M, Bell, S.E, Szubert, A.J, Navarro Coy, N, Ashcroft, A.J, Drayson, M.T, Owen, R.G, Jackson, G.H, Child, J.A

Get full text

Assessing Ventricular-Vascular Interactions After Stented Coarctation by Morgan, G.J, Slorach, C, Hui, W, Sarkola, T, Lee, K.J, Chaturvedi, R, Benson, L.N, Mertens, L, Bradley, T.J

Get full text

The safe practice of CT coronary angiography in adult patients in UK imaging departments by Harden, S.P, Bull, R.K, Bury, R.W, Castellano, E.A, Clayton, B, Hamilton, M.C.K, Morgan-Hughes, G.J, O'Regan, D, Padley, S.P.G, Roditi, G.H, Roobottom, C.A, Stirrup, J, Nicol, E.D

“…Computed tomography coronary angiography is increasingly used in imaging departments in the investigation of patients with chest pain and suspected coronary…”
Get full text

P11.05 Assessing Ventricular-Vascular Interactions after Stented Coarctation by Morgan, G. J., Slorach, C., Hui, W., Sarkola, T., Lee, K. J., Chaturvedi, R., Benson, L. N., Mertens, L., Bradley, T. J.

“…Introduction Stented coarctation is associated with increased ventricular and aortic stiffness. This study compared non-invasively determined…”
Get full text

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma by Rasche, L., Alapat, D., Kumar, M., Gershner, G., McDonald, J., Wardell, C. P., Samant, R., Van Hemert, R., Epstein, J., Williams, A. F., Thanendrarajan, S., Schinke, C., Bauer, M., Ashby, C., Tytarenko, R. G., van Rhee, F., Walker, B. A., Zangari, M., Barlogie, B., Davies, F. E., Morgan, G. J., Weinhold, N.

“…The iliac crest is the sampling site for minimal residual disease (MRD) monitoring in multiple myeloma (MM). However, the disease distribution is often…”
Get full text

Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? by Pawlyn, C, Fowkes, L, Otero, S, Jones, J R, Boyd, K D, Davies, F E, Morgan, G J, Collins, D J, Sharma, B, Riddell, A, Kaiser, M F, Messiou, C

Get full text

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma by Melchor, L, Brioli, A, Wardell, C P, Murison, A, Potter, N E, Kaiser, M F, Fryer, R A, Johnson, D C, Begum, D B, Hulkki Wilson, S, Vijayaraghavan, G, Titley, I, Cavo, M, Davies, F E, Walker, B A, Morgan, G J

“…Although intratumor heterogeneity has been inferred in multiple myeloma (MM), little is known about its subclonal phylogeny. To describe such phylogenetic…”
Get full text

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms by Walker, B A, Wardell, C P, Melchor, L, Brioli, A, Johnson, D C, Kaiser, M F, Mirabella, F, Lopez-Corral, L, Humphray, S, Murray, L, Ross, M, Bentley, D, Gutiérrez, N C, Garcia-Sanz, R, San Miguel, J, Davies, F E, Gonzalez, D, Morgan, G J

“…The mechanisms involved in the progression from monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) to malignant multiple…”
Get full text

Genetic abnormalities during transition from Helicobacter-pylori-associated gastritis to low-grade MALToma by Calvert, R, Randerson, J, Evans, P, Cawkwell, L, Lewis, F, Dixon, M F, Jack, A, Owen, R, Shiach, C, Morgan, G J

“…The helicobacter-associated transition from chronic gastritis to MALToma (lymphoma of mucosa-associated lymphoid tissue) may require genetic change in the…”
Get more information